{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:47:58Z","timestamp":1792108078486,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omton.2025.201081","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:09:16Z","timestamp":1761959356000},"page":"201081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["CD19 CAR T cell therapy BY19 for pediatric and adult patients with relapsed or refractory B cell neoplasms in Belarus: Phase 1 trial"],"prefix":"10.1016","volume":"33","author":[{"given":"Mikalai","family":"Katsin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2505-3005","authenticated-orcid":false,"given":"Dmitri","family":"Dormeshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr","family":"Migas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Karas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsiana","family":"Shman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Serada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yauheniya","family":"Khalankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Klych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dzmitry","family":"Lutskovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Lukoika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Meleshko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.201081_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3324\/haematol.2015.131680","article-title":"Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: Prognostic factors, treatment and outcome","volume":"101","author":"Oskarsson","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2025.201081_bib2","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201081_bib3","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: A report from Children\u2019s Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201081_bib4","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Hoelzer","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omton.2025.201081_bib5","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201081_bib6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2025.201081_bib7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2025.201081_bib8","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201081_bib9","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2025.201081_bib10","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.201081_bib11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.201081_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107569","article-title":"Decitabine consolidation after CD19\/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed\/refractory B-ALL patients","volume":"145","author":"Li","year":"2024","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omton.2025.201081_bib13","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2025.201081_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005678","article-title":"Dose-response correlation for CAR-T cells: A systematic review of clinical studies","volume":"10","author":"Rotte","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201081_bib15","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/bcp.14281","article-title":"Chimeric antigen receptor T-cell therapies: Optimising the dose","volume":"86","author":"Dasyam","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.omton.2025.201081_bib16","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201081_bib17","doi-asserted-by":"crossref","first-page":"11797","DOI":"10.1073\/pnas.91.25.11797","article-title":"Toxicity of 5-aza-2\u2019-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation","volume":"91","author":"J\u00fcttermann","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2025.201081_bib18","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.2147\/OTT.S198567","article-title":"Decitabine enhances cytotoxic effect of t cells with an anti-cd19 chimeric antigen receptor in treatment of lymphoma","volume":"12","author":"Li","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.omton.2025.201081_bib19","article-title":"Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2025.201081_bib20","author":"Gherardini"},{"key":"10.1016\/j.omton.2025.201081_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00281-022-00965-1","article-title":"Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy","volume":"45","author":"De Sanctis","year":"2023","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.omton.2025.201081_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40164-023-00397-z","article-title":"Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19\/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed\/refractory B-ALL patients","volume":"12","author":"Ma","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.omton.2025.201081_bib23","first-page":"592","article-title":"Plasma and Cerebrospinal Fluid Pharmacokinetics of 5-Aza-2\u2019-deoxycytidine in Rabbits and Dogs","volume":"43","author":"Chabot","year":"1983","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.201081_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074740","article-title":"CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies","volume":"13","author":"Kekre","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201081_bib25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201081_bib26","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas dos Santos","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.201081_bib27","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201081_bib33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","article-title":"Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy\u00ae: real-world experience and cost analysis in India","volume":"58","author":"Palani","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2025.201081_bib34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.leu.2402365","article-title":"Detection of mycoplasma in leukemia-lymphoma cell lines using polymerase chain reaction","volume":"16","author":"Uphoff","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2025.201081_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2017.09.001","article-title":"Detection of Replication Competent Lentivirus Using a qPCR Assay for VSV-G","volume":"8","author":"Skrdlant","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2025.201081_bib28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2025.201081_bib29","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201081_bib30","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201081_bib31","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201081_bib32","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992500150X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992500150X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:15:53Z","timestamp":1772154953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295032992500150X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S295032992500150X"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.201081","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD19 CAR T cell therapy BY19 for pediatric and adult patients with relapsed or refractory B cell neoplasms in Belarus: Phase 1 trial","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.201081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201081"}}